Hemostemix Settlement via Depository Trust Company Plus OTCQB Update

Rhea-AI Summary

Hemostemix (TSXV: HEM) (OTC: HMTXF) has announced that its common share purchases can now be settled via the Depository Trust Company (DTC). The company filed a disclosure document with OTC Markets on January 7, 2025, and expects to receive OTCIQ access and begin trading on the OTCQB exchange later in January 2025.

The company has also entered into a 12-month agreement with biotech.de until December 31, 2025, to expand its reach to German-speaking investors. The services include German translation of news and social media, co-marketing, video production, investor introductions, and content creation to promote ACP-01 therapy for various conditions including PAD, CLTI, Angina, and various cardiac conditions. Biotech.de will receive compensation of $50,000 in Hemostemix common shares, issued quarterly at market price.

Positive

• DTC settlement enablement improves trading accessibility
• Pending OTCQB uplisting expands market presence
• Strategic partnership with biotech.de opens German market exposure

Negative

• Share dilution through biotech.de compensation agreement

Calgary, Alberta--(Newsfile Corp. - January 13, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that the settlement of Hemostemix common share purchases via the Depository Trust Company ("DTC") is now enabled.

The Company filed a disclosure document with OTC Markets on Wednesday, January 7, 2025. Hemostemix expects to receive OTCIQ access this week. Upon receipt, the Company will upload its financial statements and MD&A, with the expectation of trading on the OTCQB exchange later this month.

Strategic Collaboration with biotech.de

Hemostemix has entered into a 12-month agreement with biotech.de, to December 31, 2025, to introduce and explain the Company to German-speaking investors. The services provided by biotech.de include:

1. German Translation Services - Translating all news and social media released in English.

2. Co-Marketing - Introducing the Company to biotech.de's extensive readership.

3. Video Production - Creating professional video content.

4. Investor Introductions - Arranging one-on-one meetings with select investors.

5. Editorial Content Creation - Generating articles to supplement the Company's messaging.

6. Sales Support - Developing content to promote ACP-01 therapy to no-option patients suffering from:

• Peripheral Arterial Disease (PAD)

• Chronic Limb-Threatening Ischemia (CLTI)

• Angina

• Ischemic Cardiomyopathy

• Non-Ischemic Dilated Cardiomyopathy

• Congestive Heart Failure

• Vascular Dementia

As part of this agreement, biotech.de will be compensated $50,000 in common shares of Hemostemix, issued quarterly in arrears at the then-market price, in accordance with the policies of the TSX Venture Exchange.

About Hemostemix

Founded in 2003, Hemostemix is an award-winning autologous stem cell therapy company with a patented blood-based stem cell therapeutics platform. The Company is focused on scaling therapies that include angiogenic cell precursors, neuronal cell precursors, and cardiomyocyte cell precursors.

For more information, visit www.hemostemix.com.

Contact

Thomas Smeenk, President & CEO
Email: tsmeenk@hemostemix.com
Phone: (905) 580-4170

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to sales of its lead product ACP-01, the commercialization of ACP-01 via the sale of compassionate treatments under Special Access Program. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of the litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedarplus.com. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/236953

FAQ

When will HMTXF begin trading on OTCQB?

Hemostemix expects to begin trading on the OTCQB exchange later in January 2025, following OTCIQ access approval and financial document submission.

What is the value of the biotech.de agreement for HMTXF?

The agreement is valued at $50,000, paid in common shares issued quarterly at market price, providing German market exposure and investor relations services through December 31, 2025.

What medical conditions does HMTXF's ACP-01 therapy target?

ACP-01 therapy targets Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia, Angina, Ischemic Cardiomyopathy, Non-Ischemic Dilated Cardiomyopathy, Congestive Heart Failure, and Vascular Dementia.

What services will biotech.de provide to HMTXF?

Biotech.de will provide German translation services, co-marketing, video production, investor introductions, editorial content creation, and sales support for ACP-01 therapy.